TY - JOUR
T1 - Biologics in vasculitides
T2 - Where do we stand, where do we go from now?
AU - Pazzola, Giulia
AU - Muratore, Francesco
AU - Pipitone, Nicolò
AU - Salvarani, Carlo
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.
AB - Biological agents represent a valid therapeutic option in patients with severe and/or relapsing vasculitis. Over the last years, some of these agents have become an established therapy (such as RTX in AAV or IFX for ocular BD), and some appear to hold promise to become so. In addition, there are a number of drugs in the pipeline that may contribute to further improve the prognosis of vasculitis. As the range of medications available for vasculitis widens, the need will also increase to define the best treatment schemes as well as to identify those patients that may benefit most from biological agents.
UR - http://www.scopus.com/inward/record.url?scp=84930870876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930870876&partnerID=8YFLogxK
U2 - 10.1016/j.lpm.2015.04.010
DO - 10.1016/j.lpm.2015.04.010
M3 - Article
AN - SCOPUS:84930870876
VL - 44
SP - e231-e239
JO - Nouvelle Presse Medicale
JF - Nouvelle Presse Medicale
SN - 0755-4982
IS - 6
ER -